Matches in DBpedia 2016-04 for { ?s ?p "The Center for Medicine in the Public Interest (CMPI) is a non-profit medical issues research group. It was founded by the Pacific Research Institute. CMPI's research agenda deals with clinical outcomes and econometric studies that analyze the value of new medicines and genomic and molecular-based medical innovation.CMPI is a 501(c)3 organization and as such is not permitted to devote a substantial part of its activity to lobbying. Its officers have written articles on various issues including price controls on pharmaceutical products in publicly funded healthcare schemes in the United States, and restrictions on advertising in the European Union. The Economist Intelligence Unit has written that the organisation generally takes a pro-drug industry viewpoint."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Center_for_Medicine_in_the_Public_Interest abstract "The Center for Medicine in the Public Interest (CMPI) is a non-profit medical issues research group. It was founded by the Pacific Research Institute. CMPI's research agenda deals with clinical outcomes and econometric studies that analyze the value of new medicines and genomic and molecular-based medical innovation.CMPI is a 501(c)3 organization and as such is not permitted to devote a substantial part of its activity to lobbying. Its officers have written articles on various issues including price controls on pharmaceutical products in publicly funded healthcare schemes in the United States, and restrictions on advertising in the European Union. The Economist Intelligence Unit has written that the organisation generally takes a pro-drug industry viewpoint.".
- Q5059765 abstract "The Center for Medicine in the Public Interest (CMPI) is a non-profit medical issues research group. It was founded by the Pacific Research Institute. CMPI's research agenda deals with clinical outcomes and econometric studies that analyze the value of new medicines and genomic and molecular-based medical innovation.CMPI is a 501(c)3 organization and as such is not permitted to devote a substantial part of its activity to lobbying. Its officers have written articles on various issues including price controls on pharmaceutical products in publicly funded healthcare schemes in the United States, and restrictions on advertising in the European Union. The Economist Intelligence Unit has written that the organisation generally takes a pro-drug industry viewpoint.".